Sentences with phrase «better outcomes for cancer patients»

Not exact matches

If hypofractionated radiation with curative intent can reduce the treatment time for lung cancer patients by half with no greater toxicity, and with equivalent — if not better — tumor control and survival outcomes, this research could result in a change in the paradigm of how a large subset of locally advanced NSCLC patients are treated.»

«Personalized medicine leads to better outcomes for patients with cancer.»

In addition to postoperative A-fib, researchers are studying, for example, what factors can improve outcomes of surgeries performed on weekends; how many rectal cancer operations a hospital needs to perform for the best results; and whether having a trauma department confers a beneficial «halo effect» on patient outcomes across the board.

«By reviewing studies that collectively examined vitamin D levels in 17,332 cancer patients, our analysis demonstrated that vitamin D levels are linked to better outcomes in several types of cancer,» said one of the study's authors, Hui Wang, MD, PhD, Professor of the Institute for Nutritional Sciences at the Shanghai Institutes for Biological Sciences at the Chinese Academy of Sciences in Shanghai, China.

The application of NGS to breast cancer research has enabled the development of cost - effective, multigene sequencing panels that have advanced our understanding of the disease and may in the future translate into better diagnosis and outcomes for patients.

These therapies could enhance the effects of novel cancer immunotherapies when used in combination, resulting in better health outcomes for cancer patients.

This accuracy really shows up in areas such as radiation treatment for cancer, where the dose delivered to the patient's tumour needs to be accurate to within 3 per cent to achieve the best outcome.

Dr Mattarollo said increased anxiety was natural with a cancer diagnosis, and it should be managed to ensure the best possible outcome for patients.

«Low levels of functional BRCA are associated with a greater number of clonal mutations and enhanced immune recruitment, which may explain the greater chemosensitivity of these tumors and better outcomes for patients,» explained Christos Hatzis, assistant professor of medicine and director of Breast Bioinformatics, Yale Cancer Center and senior author on the paper.

«To move the needle forward toward prolonged survival and better treatment outcomes, our research team created a combined investigational regimen for patients with locally advanced pancreatic cancer,» said Richard Tuli, MD, PhD, a radiation oncologist in the Department of Radiation Oncology and a member of the Samuel Oschin Comprehensive Cancer Instcancer,» said Richard Tuli, MD, PhD, a radiation oncologist in the Department of Radiation Oncology and a member of the Samuel Oschin Comprehensive Cancer InstCancer Institute.

Research efforts led by Dr. Elizabeth Lawlor are studying how Ewing sarcoma cancer cells are able to survive when deprived of oxygen, and whether suppression of specific proteins can address this abnormal cell survival and lead to better outcomes for patients.

The work that garnered the honor, «An analysis of the risk and benefit of neoadjuvant chemotherapy among patients undergoing surgery for non-small cell lung cancer,» examined data from more than 134,000 patients in the National Cancer Database to assess the impact of neoadjuvant therapy on perioperative outcomes, as well as long - term surcancer,» examined data from more than 134,000 patients in the National Cancer Database to assess the impact of neoadjuvant therapy on perioperative outcomes, as well as long - term surCancer Database to assess the impact of neoadjuvant therapy on perioperative outcomes, as well as long - term survival.

Although this approach has yet to be tested in humans, this study suggests that combining two existing cancer immunotherapies can significantly boost their efficacy, resulting in better outcomes for patients.

I think we all agree that we over treat prostate cancer in this country compared to what you see in Europe with similar outcomes and so but I think this is where the human or the Cancer Genome Project or at least better biomarkers for looking at mutations that we already know occur in these diseases I think hopefully within the next few years every single patient who is diagnosed with prostate cancer those biopsies will be characterized and then the patients followed, hopefully watchful waiting and we'll ultimately get a correlation between what mutational events predict a rather dormant disease as opposed to a very aggressive dicancer in this country compared to what you see in Europe with similar outcomes and so but I think this is where the human or the Cancer Genome Project or at least better biomarkers for looking at mutations that we already know occur in these diseases I think hopefully within the next few years every single patient who is diagnosed with prostate cancer those biopsies will be characterized and then the patients followed, hopefully watchful waiting and we'll ultimately get a correlation between what mutational events predict a rather dormant disease as opposed to a very aggressive diCancer Genome Project or at least better biomarkers for looking at mutations that we already know occur in these diseases I think hopefully within the next few years every single patient who is diagnosed with prostate cancer those biopsies will be characterized and then the patients followed, hopefully watchful waiting and we'll ultimately get a correlation between what mutational events predict a rather dormant disease as opposed to a very aggressive dicancer those biopsies will be characterized and then the patients followed, hopefully watchful waiting and we'll ultimately get a correlation between what mutational events predict a rather dormant disease as opposed to a very aggressive disease.

The approach is to use clinically relevant tumor models such as patient - derived xenografts (PDXs), as well as humanized and immunocompetent transgenic tumor - bearing mice to design rational combinations of novel and emerging cancer therapies, including tumor - targeting and immune - stimulating therapies, to ultimately improve treatment outcomes for cancer patients.

At UT Southwestern, our specialized liver cancer team comprises transplant hepatologists, surgeons, medical and radiation oncologists, interventional radiologists, and other specialists, all working together to deliver individualized patient care and bring about the best possible outcomes for patients with any type of liver cancer.

Ultimately the results will help the field of cancer research to learn how to combine and develop different therapies to achieve better clinical outcomes for leukaemia patients.

Recognizing the factors that make a patient a candidate for hereditary cancer testing is critical to preventing the disease, delaying its onset, or diagnosing cancer at an earlier stage, while better outcomes may still be achievable.